Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Broccoli, Alessandro"'
Publikováno v:
Best Practice & Research Clinical Haematology. 31:241-250
The unique biological features of primary mediastinal large B-cell lymphoma are offering suggestions for the development and application of innovative drugs in patients who do not respond to first-line regimens or relapse. This lymphoma, in fact, is
Autor:
Nicola Cascavilla, Cristina Tecchio, Carlo Visco, Annalisa Chiappella, Maria Christina Cox, Roberto Marasca, Rossella Paolini, Beatrice Casadei, Gerardo Musuraca, Caterina Patti, Michelle Zancanella, Annarita Conconi, Maria Goldaniga, Angelo Fama, Dario Marino, Francesco Gaudio, Claudia Castellino, Alessandra Romano, Luigi Rigacci, Monica Tani, Monica Balzarotti, Federico Monaco, Alessandro Broccoli, Lisa Argnani, Liliana Devizzi, Pier Luigi Zinzani
Background Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma subtype, and approximately 50% of the patients are >60 years of age. Patients with relapsed/refractory (rr) disease have a poor prognosis with currently availabl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98a63b4ae6076e247de8356a0953673f
https://europepmc.org/articles/PMC6738312/
https://europepmc.org/articles/PMC6738312/
Autor:
Pier Luigi Zinzani, Beatrice Casadei, Lisa Argnani, Federica Quirini, Alice Morigi, Miriam Marangon, Vittorio Stefoni, Alessandro Broccoli, Cinzia Pellegrini, Lorenzo Tonialini
Publikováno v:
BMC Cancer
BMC Cancer, Vol 17, Iss 1, Pp 1-8 (2017)
BMC Cancer, Vol 17, Iss 1, Pp 1-8 (2017)
Background The purpose of this study is to investigate the most suitable first-line approach and the best combination treatment for primary mediastinal large B-cell lymphoma (PMLBCL) as they have been matter of debate for at least two decades. Method
Autor:
Vittorio Stefoni, Letizia Gandolfi, Pier Luigi Zinzani, Gianluca Gaidano, Lisa Argnani, Chiara Bottelli, Beatrice Casadei, Alessandro Broccoli, Chiara Ciochetto, Cinzia Pellegrini, Maria Giuseppina Cabras, Michela Ansuinelli
Publikováno v:
Blood Cancer Journal
An update at 7 years was conceived for our multicenter phase II study in which 55 elderly high-risk untreated diffuse large B-cell lymphoma patients were treated with 90Y-ibritumomab tiuxetan after a short course of rituximab, cyclophosphamide, doxor